Atomoxetine for ATS and Opioid Dependence During Buprenorphine Maintenance Treatment in Malaysia
- Registration Number
- NCT01863251
- Lead Sponsor
- Yale University
- Brief Summary
To evaluate the tolerability, acceptability and potential effect size of the efficacy of 4 months of atomoxetine treatment for patients with co-occurring ATS and heroin dependence (COATS) receiving buprenorphine maintenance treatment (BMT) and educational drug and HIV risk reduction counseling (EDRC).
- Detailed Description
The Specific Aims of the proposed study are:
1. To evaluate the tolerability, acceptability and potential effect size of the efficacy of 4 months of atomoxetine treatment for patients with co-occurring ATS and heroin dependence (COATS) receiving buprenorphine maintenance treatment (BMT) and educational drug and HIV risk reduction counseling (EDRC).
2. To better characterize patients with co-occurring ATS and heroin dependence (with regard to disturbances of mood, impulse control, executive functioning and patterns of drug use during MMT) and to evaluate the effects of atomoxetine on mood, impulsivity, and executive functioning (including attention, concentration, memory, and decision-making characteristics).
3. To provide training in drug abuse treatment, HIV prevention and treatment, and drug abuse clinical research to drug abuse clinical researchers and clinicians in Kota Bharu, Malaysia.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 90
- Meet Opioid and Amphetamine-type stimulant (ATS)dependence, as assessed by the Structured Clinical Interview for Diagnostic and Statistical Manual (DSM-IV) (SCID) and documented by opioid-positive and ATS positive urine tests.
- Report at least 2 or more days per week of ATS use over the past month.
- Hypersensitivity to atomoxetine;
- Current use of a monoamine oxidase inhibitor (MAOI) or use within the preceding 2 weeks;
- Suffer from narrow angle glaucoma; pheochromocytoma; severe cardiovascular disorder; liver enzymes greater than 3 times the upper limit of normal; liver failure or acute hepatitis;
- Pregnancy or breast feeding;
- Current suicide or homicide risk;
- Current psychotic disorder or major depression;
- Inability to understand the protocol or assessment questions.
- A physician reviews the results of all baseline assessments and laboratory and other medical tests (CBC, chemistries, liver enzymes, HIV and Hepatitis B and C, EKG, chest x-ray), takes a medical history, and performs a physical examination in order to confirm the patient's eligibility for the study.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- FACTORIAL
- Arm && Interventions
Group Intervention Description Placebo Atomoxetine Placebo inactive medication Atomoxetine Atomoxetine Patients assigned to atomoxetine will receive atomoxetine 40 mg daily, beginning on Day 5. Atomoxetine dose will be increased to 80 mg daily for all patients beginning on Day 12. Atomoxetine will be increased to 120 mg daily for patients with persistent ATS use after 4 weeks of treatment.
- Primary Outcome Measures
Name Time Method ATS (Amphetamine-type stimulant) Use 4 months The primary evaluation of the effect size in the proposed study will be based on the overall proportions of urine tests negative for ATS and days per month abstinent from ATS use during the 16 week active study period.
- Secondary Outcome Measures
Name Time Method Retention 4 months treatment retention
HIV Risks 4 months Reductions in HIV Risk Behaviors, as assessed by computer-assisted self-report inventory
Functional status 4 months changes in functional outcomes (assessed by the ASI).
Trial Locations
- Locations (1)
Universiti Sains Malaysia
🇲🇾Kota Bharu, Malaysia